Non-Patent Exclusivity Period Proposed For Biologics In Face Of Follow-Ons
Executive Summary
A period of non-patent exclusivity for biologic products is necessary to preserve incentives for innovation in the face of follow-on biologics, attorneys argue in an article in the March/April issue of Health Affairs